X0202 SCHEDULE 13G 0001442891 XXXXXXXX LIVE Common Stock, par value $0.001 per share 03/31/2026 0001636651 Ovid Therapeutics Inc. 690469101 441 Ninth Avenue, 14th floor New York NY 10001 Rule 13d-1(b) Eventide Asset Management, LLC DE 12773577.00 0.00 12773577.00 0.00 12773577.00 N 7.3 IA Finny Kuruvilla, M.D., Ph. D. X1 0.00 12773577.00 0.00 12773577.00 12773577.00 N 7.3 HC IN Robin C. John X1 0.00 12773577.00 0.00 12773577.00 12773577.00 N 7.3 HC IN Ovid Therapeutics Inc. 441 Ninth Avenue, 14th floor, New York, NY 10001 (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John") Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110 Eventide: Delaware Kuruvilla: United States John: United States N IA HC (i) Eventide: 12,773,577 (ii) Kuruvilla: 12,773,577 (iii) John: 12,773,577 (i) Eventide: 7.3% (ii) Kuruvilla: 7.3% (iii) John: 7.3% (1) Eventide: 12,773,577 (2) Kuruvilla: 0 (3) John: 0 (1) Eventide: 0 (2) Kuruvilla: 12,773,577 (3) John: 12,773,577 (1) Eventide: 12,773,577 (2) Kuruvilla: 0 (3) John: 0 (1) Eventide: 0 (2) Kuruvilla: 12,773,577 (3) John: 12,773,577 Y N As of March 31, 2026, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 12,773,577 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Healthcare & Life Sciences Fund which is a registered investment company. As of March 31, 2026, the Eventide Healthcare & Life Sciences Fund held 12,773,577 shares of the Issuer's Common Stock, representing 7.3% of the Issuer's outstanding Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities. EXHIBIT 1 - Filed Herewith Eventide Asset Management, LLC /s/ Peter J. Luiso 05/15/2026 Finny Kuruvilla, M.D., Ph. D. /s/ Finny Kuruvilla, M.D., Ph. D. 05/15/2026 Robin C. John /s/ Robin C. John 05/15/2026